Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients
Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study
Read More
Tag: ABX464
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
